Search Results
Your search for The ASCO matches 21433 pages
Showing 13501 - 13550Prostate-Specific Antigen Testing Rates Appear to Level Off After Recent Drop
Declines in prostate-specific antigen (PSA) testing that came after changes in government screening guidelines have abated in recent years, according to a new study. In JAMA Internal Medicine, American Cancer Society (ACS) investigators led by Stacy A. Fedewa, PhD, wrote that about 1 in 3 men aged...
Complete Surgical Metastasectomy for Patients With Metastatic Renal Cell Carcinoma May Extend Life Expectancy
Mayo Clinic researchers have discovered that surgery could more than double life expectancy for many patients with late-stage kidney cancer, giving them anywhere from 2 to almost 10 years more than they would have without the surgery. A paper published by Zaid et al in The Journal of Urology found...
FDA Approves Brigatinib for Metastatic ALK-Positive Non–Small Cell Lung Cancer
On April 28, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brigatinib (Alunbrig) for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) who have had disease progression on or are...
FDA Approves Midostaurin in Combination With Chemotherapy for Newly Diagnosed FLT3-Positive Acute Myeloid Leukemia
On April 28, 2017, the U.S. Food and Drug Administration (FDA) approved midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation–positive, as detected by an FDA-approved test, in combination with standard cytarabine and...
Second Cancers May Be Deadlier in Pediatric, Adolescent, and Young Adult Patients
Second cancers in children as well as adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients aged 15 to 39 years overall, according to a new study by University of California (UC), Davis...
FDA Grants Lorlatinib Breakthrough Therapy Designation for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On April 27, the investigational next-generation ALK/ROS1 tyrosine kinase inhibitor lorlatinib was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell...
New 'Bone-in Culture Array' Tests Therapies for Breast Cancer Metastasis
A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone. Findings of this research were published by Wang et al in Nature Communications....
FDA Expands Approved Use of Regorafenib for Hepatocellular Carcinoma
The U.S. Food and Drug Administration (FDA) has expanded the approved use of regorafinib (Stivarga) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib (Nexavar). This is the first new FDA-approved treatment for liver cancer in...
ELCC 2017: Patients With Lung Cancer Treated With PD-1/PD-L1 Checkpoint Inhibitors May Experience Adverse Events After Influenza Vaccination
Patients with lung cancer treated with programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect. The results, to ...
Joint Position Statement on Management of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Hormone-Sensitive Breast Cancer
A new position statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated with aromatase inhibitors and outlines key management strategies to help prevent bone loss and related fractures. It was published by Hadji et...
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...
FDA Takes Action Against 14 Companies for Selling Illegal Cancer Treatments
On April 25, the U.S. Food and Drug Administration (FDA) posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat, or cure cancer. The products are marketed and sold without FDA approval, most commonly on ...
ILC 2017: Selective Internal Radiation Therapy vs Sorafenib in Hepatocellular Carcinoma
Results of the SARAH trial presented at the 2017 International Liver Congress (ILC) demonstrated that selective internal radiation therapy (SIRT) resulted in a median overall survival of 8.0 months compared to 9.9 months with sorafenib (Nexavar; P = .179) in patients with locally advanced ...
Noninvasive Imaging Test May Accurately Rule Out Kidney Cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT (single-photon emission computed tomography plus computed tomography) to conventional CT or magnetic resonance imaging...
NCCN Survey Reveals Oncology Community Professionals’ Concerns About Financial Distress, Access to Care
Oncology community professionals are concerned about the ability of their patients to access cancer screening and treatment under the proposed American Health Care Act (AHCA), according to a survey conducted March 23–24, 2017, at the National Comprehensive Cancer Network® (NCCN®) 22nd ...
Low Cervical Cancer Screening Rates Found Among Women With Severe Mental Illness
Women enrolled in California's Medicaid program (Medi-Cal) who have been diagnosed with severe mental illness have been screened for cervical cancer at much lower rates than other women, according to a new study by researchers at the University of California, San Francisco (UCSF), published by...
Multigene Test Could Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer
New research indicates that testing for variants in seven cancer-associated genes (instead of the usual process of testing in just two genes) followed by risk-reduction management could cost-effectively improve life expectancy for women at risk of hereditary breast cancer. The findings were...
Higher Rates of Bone Metastases and Increased Risk of Death in Follicular and Medullary Thyroid Cancer
In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death....
Breast Cancer Rates Increasing Among Asian Americans
In contrast to other racial/ethnic groups in the United States, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years, according to findings published by Gomez et al in Breast Cancer Research and Treatment. To better understand potential contributors to...
21-Gene Assay Score and Chemotherapy Decision-Making in Node-Positive Early Breast Cancer
The 21-gene recurrence score assay, Oncotype DX, determines a score that estimates the likelihood of distant recurrence of disease in women with early-stage estrogen receptor–positive breast cancer; this score is used to assess the benefit of adjuvant chemotherapy. Testing with this assay is...
Study Associates Comorbidities With Survival Outcomes in Women With Ovarian Cancer
Research from epidemiologists at Roswell Park Cancer Institute, published by Minlikeeva et al in Cancer Causes & Control, suggests that hypertension and diabetes and the use of medications to treat these comorbidities may have an effect on survival outcomes in women with ovarian cancer. Study...
Update to ASCO Clinical Practice Guideline on Potentially Curable Pancreatic Cancer
An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The updated recommendation (4.1) modifies the...
Keith T. Flaherty, MD, Named New Editor-in-Chief of Clinical Cancer Research
The American Association for Cancer Research (AACR) recently announced the appointment of Keith T. Flaherty, MD, as Editor-in-Chief of Clinical Cancer Research. Dr. Flaherty is Director of the Termeer Center for Targeted Therapies and Director of Clinical Research at the Massachusetts General...
More on Treatment Decisions in Esophageal Cancer
In the March 25, 2017, issue of The ASCO Post, Steven H. Lin, MD, PhD, shared his thoughts on the role of positron-emission tomography (PET) in assessing response to induction chemotherapy in patients with resectable esophageal or gastroesophageal junction cancer. He noted that complete pathologic...
Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered
An article that appeared in the April 10 issue of The ASCO Post (“Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer”) suggests unwarranted conclusions from the phase III SOLO2 trial of olaparib (Lynparza) in patients with platinum-sensitive relapsed ovarian cancer and...
Addition of Buparlisib to Paclitaxel in Squamous Cell Carcinoma of the Head and Neck
In the phase II BERIL-1 trial reported in The Lancet Oncology, Soulières et al found that adding the pan-PI3K (phosphatidylinositol 3-kinase) inhibitor buparlisib to paclitaxel improved outcomes in patients with platinum-pretreated recurrent metastatic squamous cell carcinoma of the head and neck....
Adding Bevacizumab to Cisplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer
In an Italian phase III trial reported in the Journal of Clinical Oncology, Marcello Tiseo, MD, of Azienda Ospedaliero-Universitaria, Parma, Italy, and colleagues found that adding first-line bevacizumab (Avastin) to cisplatin/etoposide did not prolong overall survival in patients with...
Link Between Obesity and Transformation of MGUS to Myeloma
In a population-based cohort study reported in the Journal of the National Cancer Institute, Su-Hsin Chang, PhD, of the Washington University School of Medicine, and colleagues found that overweight and obesity were associated with an increased risk of transformation of monoclonal gammopathy of...
Leonard I. Zon, MD, Honored With 2017 AACR–Irving Weinstein Foundation Distinguished Lecture
The American Association for Cancer Research (AACR) awarded the 13th AACR–Irving Weinstein Foundation Distinguished Lectureship to Leonard I. Zon, MD, Grousbeck Professor of Pediatrics at Harvard Medical School, Director of the Stem Cell Program at Boston Children’s Hospital, and a Howard Hughes...
Expect Questions About Continued Risk of Melanoma
Survivors of melanoma are more likely to limit their exposure to ultraviolet radiation than those who have not had the disease, but more than 10% continue to intentionally tan, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The study surveyed 724 people diagnosed ...
Some Melanoma Survivors Continue to Seek Sun Exposure, Risking Second, Potentially More Serious Melanoma
Long-term survivors of melanoma are more likely than those who have not been diagnosed with the disease to use sunscreen, protective clothing, and other means to limit exposure to the sun, according to a survey of melanoma survivors and controls about ultraviolet radiation exposure and protective...
Roger S. Lo, MD, PhD, Receives Inaugural AACR–Waun Ki Hong Award for Cancer Research
The American Association for Cancer Research (AACR) honored Roger S. Lo, MD, PhD, with the first AACR–Waun Ki Hong Award for Outstanding Achievement in Cancer Research during the 2017 AACR Annual Meeting in Washington, DC. The AACR established this award in recognition of AACR President...
Living Beyond Breast Cancer Translates Metastatic Breast Cancer Guide Into Five Languages
Living Beyond Breast Cancer (LBBC) has translated its Metastatic Breast Cancer Series: Guide for the Newly Diagnosed into the five most-often-spoken languages in the United States after English: Spanish, Chinese, Vietnamese, Tagalog, and French. Jointly created by LBBC and the Metastatic Breast...
Carlo M. Croce, MD, FAACR, Recognized With 2017 AACR Margaret Foti Award
The American Association for Cancer Research (AACR) recognized Carlo M. Croce, MD, FAACR, with the 11th Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2017 in Washington, DC. The Margaret Foti Award for Leadership and...
Trastuzumab Biosimilar Could Lead to Lower Health-Care Costs and Greater Drug Access for Patients With Metastatic Breast Cancer
The human epidermal growth factor receptor (HER) family consists of four members—epidermal growth factor receptor (EGFR), HER2, HER3, and HER4—all transmembrane receptor tyrosine kinases, which regulate cell growth and survival, differentiation, and migration, as well as other cellular responses.1 ...
Monoclonal Antibody Therapy With Daratumumab in Multiple Myeloma: Expanding Therapeutic Horizons
The advent of successful monoclonal antibody therapy in the treatment of relapsed/refractory myeloma has dramatically improved the prognosis of patients for whom currently approved novel therapies have failed. In 2015, the approval of the combination of elotuzumab (Empliciti) with lenalidomide...
Study Projects HIV-Related Cancer Burden to Decline
The total number of cancer cases diagnosed among people living with the human immunodeficiency virus (HIV) is projected to decline in coming years, due mostly to declines in non-Hodgkin lymphoma and Kaposi sarcoma. Certain other cancers, such as prostate and lung, are expected to rise, according to ...
Treating Human Immunodeficiency Virus–Related Lymphoma
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Judy E. Garber, MD, MPH, Receives AACR Joseph H. Burchenal Memorial Award
Judy E. Garber, MD, MPH, Director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute, has been honored by the American Association for Cancer Research (AACR) for outstanding achievement in clinical cancer research. Dr. Garber, a medical oncologist and clinical cancer...
NCCN Foundation Board of Directors Names New Leadership
The NCCN Foundation® has named Gena Cook, Cofounder and Chief Executive Officer of Navigating Cancer, as Chair of the National Comprehensive Cancer Network® (NCCN®) Foundation Board of Directors. Ms. Cook, who was elected to the Board in 2010, succeeds Ellen O. Tauscher, former U.S....
Stage I Lung Cancer: Treatment Advances Have Changed the Game
Read more in the Journal of Oncology Practice (JOP). Visit ASCOPubs.org/journal/jop Patients with stage I lung cancer are achieving excellent local tumor control, thanks to an evolution in radiotherapy and surgical approaches. Jeffrey A. Bogart, MD, Professor and Chair of the Department of...
Institute for Clinical Immuno-Oncology White Paper Highlights Challenges, Progress, and Priorities in Immunotherapy
Momentum around immunotherapies for cancer continues to build, but the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care. As these therapies are increasingly integrated into practice, all stakeholders—providers, patients,...
Ophira Ginsburg, MD, to Lead New High Risk Program at NYU Langone’s Perlmutter Cancer Center
Medical oncologist Ophira Ginsburg, MD, has joined New York University (NYU) Langone’s Perlmutter Cancer Center as Director of its new High Risk Program, which identifies, studies, and cares for patients with hereditary syndromes that increase cancer risk. Dr. Ginsburg also holds a faculty...
David M. Livingston, MD, Receives AACR International Award
David M. Livingston, MD, a cancer biologist at Dana-Farber Cancer Institute, has won a major award for discoveries in cancer research from the American Association for Cancer Research (AACR). He received the Pezcoller Foundation–AACR International Award at the AACR Annual Meeting in Washington,...
Expert Point of Review: Amrita Krishnan, MD
Amrita Krishnan, MD, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at the City of Hope in Duarte, California, told The ASCO Post that the most exciting drug in the “New Agents” session she moderated at the 2016 American Society of Hematology (ASH) Annual Meeting...
FNIH Awards Lurie Prize in Biomedical Sciences to David M. Sabatini, MD, PhD
The Foundation for the National Institutes of Health (FNIH) has selected David M. Sabatini, MD, PhD, to receive its 5th annual Lurie Prize in Biomedical Sciences for discovery of the mTOR (mechanistic target of rapamycin) cellular pathway as a key regulator of growth and metabolism in response to...
ASCO Selects 2017–2018 Health Policy Fellows
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its second year. The fellowship, aimed at early career oncologists, provides the skills necessary to monitor and shape the regulatory and ...
Different Subtypes of Acute Myeloid Leukemia Create Both Clinical and Research Challenges
Acute myeloid leukemia (AML) is the most common leukemia in adults. Each year, about 20,000 Americans will be diagnosed with AML, and roughly 10,000 people in this country will die of the disease. AML progresses quickly, and unless treatment begins soon and is effective , the prognosis is grim....
Study Finds Link Between Telomere Length and Sociodemographic Circumstances Linked to Neighborhood
Researchers at Fox Chase Cancer Center have begun to establish a biologic basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Program at Fox Chase, led a team...
Roswell Park Names Chair of Cancer Genetics and Genomics
John Krolewski, MD, PhD, has been appointed as Chair of the Department of Cancer Genetics and Genomics and Co-Leader of the Cancer Center Support Grant (CCSG) Genetics and Genomics Program at Roswell Park Cancer Institute. He will also hold the John & Santa Palisano Endowed Chair of Cancer...
